TWiV 1078: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin reviews recent measles outbreaks, prequalification of nOPV2 by the WHO and most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US before discussing COVID-19 deaths linked to SNPs in C-reactive protein, spread of recent viral variants, how early vaccination reduced hospitalization of those infected with XBB.1.5, reviewed quarantine guidelines, how oral antivirals reduce hospitalizations, dissociation of antiviral treatment from infection rebound, and long COVID, deaths due to administration of hydroxychloroquine, muscle abnormalities and extreme fatigue in individuals with long COVID-19 and how the economics of where you live make long COVID-19 more severe.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• A national measles campaign (CDC)
• A nation of measles (CDC)
• The measles unvaccinated in NY (CNN)
• Philadelphia’s measles story (Phila gov)
• January’s measles outbreak (CNN)
• Prequalify of nOPV2 by WHO (GPEI)
• Did you prequalify for the novel poliovirus vaccine (CIDRAP)
• Respiratory  disease surveillance (CDC)
• RSV surveillance  (CDC)
• RSV national trend(CDC)
• Influenza/flu surveillance  (CDC)
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend (CDC)
• COVID-19 wastewater testing (biobot)
• Death rate and C-reactive protein SNPs and COVID-19 (Scientific Reports)
• Variant tracker (CDC)
• Tracking variant hospitalizations (CDC)
• Early vaccination against XBB.1.5 hospitalization (Eurosurveillance)
• Vaccination dashboard (Netherlands)
• Quarantine/isolation guidelines (CDC)
• Antiviral gap among the non-hospitalized high risk adults (CID)
• Oral antivirals prevent hospitalization (medRxiv)
• Rebound with and without oral antivirals (MMWR)
• Randomized rebound trials (MMWR)
• Know your COVID-19 tools (ESMED)
• The PASC-paxlovid relationship (JAMA)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma remmendation for immunocompromised (IDSociety)
• Fluvoxamine for COVID-19 outpatient (RMV)
• Death by hydroxychloroquine (Biomedicine & Pharmacotherapy)
• Steroids, dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Doxycycline for prevention of progression of COVID-19 (PLoS One)
• Muscle abnormalities in long COVID (Nat Comm)
• Discovery of persistent fatigue in long COVID-19 (Amsterdam Univ Med Crr)
• IMPACC study post-acute sequelae results (Nat Comm)
• Double course of long COVID in low income countries (Nat)
• Contribute to our MicrobeTV fundraiser at PWB
• Letters read on TWiV 1078
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]